GH

Guardant Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

109.80
-0.35
-0.32%
After Hours: 109.80 0 0.00% 16:04 07/30 EDT
OPEN
109.85
PREV CLOSE
110.15
HIGH
112.20
LOW
109.12
VOLUME
511.10K
TURNOVER
--
52 WEEK HIGH
181.07
52 WEEK LOW
77.69
MARKET CAP
11.10B
P/E (TTM)
-32.5565
1D
5D
1M
3M
1Y
5Y
Bear of the Day: NeoGenomics (NEO)
Zacks.com · 1d ago
Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 2d ago
Guardant Health invests in South Korea AI-powered cancer solutions company
4X-image/iStock via Getty Images Guardant Health ([[GH]] -0.1%) has made a $26M investment in Lunit, a South Korea-based artificial intelligence-powered cancer solutions company. The investment also includes a collaboration between
Seekingalpha · 07/19 15:25
Lunit Reports $26M Strategic Investment From Guardant Health, No Terms Disclosed
Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The deal, which includes
Benzinga · 07/19 13:32
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round
Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company.
PR Newswire · 07/19 13:30
Guardant Health Invests $26 Million in Medical Startup Lunit
MT Newswires · 07/19 11:50
Bull of the Day: Exact Sciences (EXAS)
Zacks.com · 07/19 09:20
Carnegie Capital Asset Management, LLC Buys Shoals Technologies Group Inc, Guardant Health Inc, ...
GuruFocus News · 07/16 22:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GH. Analyze the recent business situations of Guardant Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GH stock price target is 170.08 with a high estimate of 195.00 and a low estimate of 150.00.
EPS
Institutional Holdings
Institutions: 540
Institutional Holdings: 95.34M
% Owned: 94.28%
Shares Outstanding: 101.12M
TypeInstitutionsShares
Increased
139
10.47M
New
60
1.31M
Decreased
152
6.42M
Sold Out
56
1.21M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/President/Chief Operating Officer/Director
AmirAli Talasaz
Chief Executive Officer/Director
Helmy Eltoukhy
Chief Financial Officer
Michael Bell
Senior Vice President/General Counsel/Secretary
John Saia
Other
Craig Eagle
Other
Michael Wiley
Lead Director/Independent Director
Ian Clark
Independent Director
Vijaya Gadde
Independent Director
Bahija Jallal
Independent Director
Samir Kaul
Independent Director
Stanley Meresman
No Data
About GH
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Webull offers kinds of Guardant Health Inc stock information, including NASDAQ:GH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GH stock methods without spending real money on the virtual paper trading platform.